Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.
LaRochelle O, Bertoli S, Vergez F, Sarry JE, Mansat-De Mas V, Dobbelstein S, Dastugue N, Strzelecki AC, Cavelier C, Creancier L, Pillon A, Kruczynski A, Demur C, Sarry A, Huguet F, Huynh A, Récher C, Delabesse E.
LaRochelle O, et al. Among authors: pillon a.
Oncotarget. 2011 Nov;2(11):850-61. doi: 10.18632/oncotarget.347.
Oncotarget. 2011.
PMID: 22081665
Free PMC article.